KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) FCF Margin (2019 - 2025)

Historic FCF Margin for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to 4.91%.

  • Esperion Therapeutics' FCF Margin rose 638000.0% to 4.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 30.71%, marking a year-over-year decrease of 218800.0%. This contributed to the annual value of 7.21% for FY2024, which is 1092500.0% up from last year.
  • Latest data reveals that Esperion Therapeutics reported FCF Margin of 4.91% as of Q3 2025, which was up 638000.0% from 38.14% recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' FCF Margin registered a high of 38.94% during Q1 2024, and its lowest value of 1116.42% during Q1 2021.
  • Its 5-year average for FCF Margin is 193.4%, with a median of 114.9% in 2023.
  • The largest annual percentage gain for Esperion Therapeutics' FCF Margin in the last 5 years was 26746100bps (2021), contrasted with its biggest fall of -1832300bps (2021).
  • Esperion Therapeutics' FCF Margin (Quarter) stood at 374.69% in 2021, then soared by 40bps to 225.7% in 2022, then soared by 49bps to 114.9% in 2023, then skyrocketed by 56bps to 50.57% in 2024, then soared by 90bps to 4.91% in 2025.
  • Its FCF Margin was 4.91% in Q3 2025, compared to 38.14% in Q2 2025 and 34.81% in Q1 2025.